Innocan Pharma Corp
CNSX:INNO
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IL |
I
|
Innocan Pharma Corp
CNSX:INNO
|
27.4m CAD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
924.3B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
575.3B USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
409.4B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
279.8B CHF |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
239.5B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
230.1B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
286.9B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
Market Distribution
| Min | -11 239.1% |
| 30th Percentile | 17.6% |
| Median | 29.8% |
| 70th Percentile | 50.4% |
| Max | 208.2% |
Other Profitability Ratios
Innocan Pharma Corp
Glance View
InnoCan Pharma Corp. focuses on the development and sale of CBD-integrated pharmaceuticals including topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The company operates through three distinct operating segments: Research, Development, Marketing, Distribution and sales of InnoCan-branded over the counter (OTC) pharmaceutical products; Research and Development of Non-pharmaceutical products for third parties and Research and Development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales. The firm is developing an OTC topical treatments product line and new platform to facilitate the targeted controlled administration of cannabinoids via injection.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Innocan Pharma Corp is 88.5%, which is below its 3-year median of 89.7%.
Over the last 3 years, Innocan Pharma Corp’s Gross Margin has increased from 40.3% to 88.5%. During this period, it reached a low of 40.3% on Sep 30, 2022 and a high of 93.8% on Sep 30, 2023.
